Multidrug Resistance-Associated Protein 1 Predicts Relapse in Iranian Childhood Acute Lymphoblastic Leukemia

• DOI: 10.7314/apjcp.2012.13.5.2285
• Publication Date: 2012-10-11T12:10:33Z
• Authors: Frouzandeh Mahjoubi; Soodeh Akbari
• Keywords: Male; ATP Binding Cassette Transporter, Subfamily B; Adolescent; Reverse Transcriptase Polymerase Chain Reaction; Remission Induction; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Drug Resistance, Multiple; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; Drug Resistance, Neoplasm; Case-Control Studies; Child, Preschool; Humans; Female; ATP Binding Cassette Transporter, Subfamily B, Member 1; RNA, Messenger; Neoplasm Recurrence, Local; Child; Follow-Up Studies; Neoplasm Staging

Multidrug resistance (MDR) is a main cause of failure in the chemotherapeutic treatment of malignant disorders. One of the well-known genes responsible for drug resistance encodes the multidrug resistance- associated protein (MRP1). The association of MRP1 with clinical drug resistance has not systematically been investigated in Iranian pediatric leukemia patients. We therefore applied real-time RT-PCR technology to study the association between the MRP1 gene and MDR phenotype in Iranian pediatric leukemia patients. We found that overexpression of MRP1 occurred in most Iranian pediatric leukemia patients at relapse. However, no relation between MRP1 mRNA levels and other clinical characteristics, including cytogenetic subgroups and FAB subtypes, was found.